IKENA ONCOLOGY INC (IKNA) Stock News
NASDAQ:IKNA - Nasdaq - US45175G1085 - Common Stock - Currency: USD
IKNA Latest News, Press Relases and Analysis
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended...
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
Ikena Oncology Reports Third Quarter 2024 Financial Results
Strong financial position with $138 million in cash and investments at close of third quarter...
IKNA Stock Earnings: Ikena Oncology Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ikena Oncology (NASDAQ:IKNA) just reported results for the second quarter of 20...
IKNA Stock Earnings: Ikena Oncology Beats EPS for Q2 2024
IKNA stock results show that Ikena Oncology beat analyst estimates for earnings per share the second quarter of 2024.
Ikena Oncology Reports Third Quarter 2024 Financial Results
Strong financial position with $138 million in cash and investments at close of third quarter
Ikena Oncology Reports Second Quarter 2024 Financial Results
Strong financial position with $145 million in cash and investments at close of second quarter...
Ikena Oncology Reports Second Quarter 2024 Financial Results
Strong financial position with $145 million in cash and investments at close of second quarter
Ikena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It 'Disappointing'
Ikena Oncology halts its IK-930 program after reviewing clinical data and resources, focusing on the novel MEK-RAF molecular glue, IK-595.
IKNA Stock Earnings: Ikena Oncology Beats EPS for Q1 2024
IKNA stock results show that Ikena Oncology beat analyst estimates for earnings per share the first quarter of 2024.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to start the day with a breakdown of the biggest pre-market stock movers traders are going to want to watch on Wednesday morning!
UPDATE – Ikena Oncology Announces Strategic Update
UPDATE – Ikena Oncology Announces Strategic Update
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date ...
Ikena Oncology Announces Strategic Update
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date ...
Ikena Oncology Announces Strategic Update
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program...
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in...
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024...
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in...
Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise Dr....
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
Ikena to cut 35% of workforce, extend cash runway into 2H 2026 (NASDAQ:IKNA)
Ikena Oncology (IKNA) plans to cut its workforce by 35% to focus on its two lead drug programs, which will extend its cash runway into 2H 2026. Read more here.
Ikena Oncology Outlines Key Priorities and Provides Corporate Updates
IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety...